Navigation Links
VirtualScopics' Project Balance Exceeds a Record $31 Million
Date:4/1/2009

Over 120% increase compared to prior year

ROCHESTER, N.Y., April 1 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, today announced that its project balance (the amount remaining to be recognized from its active and awarded projects and commonly referred to as backlog within the clinical research industry), exceeds $31 million which compares to $13.7 million at the same time a year ago, a greater than 120% increase. The average duration of the studies included within the backlog is 4-1/2 years. The company anticipates that the awarded contracts included in the project balance will be signed within the next several months as the projects near their start dates.

"We are gratified with the more than doubling of our project balance over the past year. This significant increase directly indicates the confidence our customers have in our people, technology, operational reach, and overall capability to deliver results they can count on to make the important decisions required with today's complex study designs," said Jeff Markin, VirtualScopics' president and chief executive officer. He added, "With the depressed global economic environment, we are especially encouraged at the growth we are seeing and remain optimistic with our 2009 projections."

Vice President of Business Development, Rosemary Shull, stated "An exciting component of our project balance is the growing percentage of studies that originated outside the United States. Currently, over 30% of our awarded contracts are from customers overseas." She added, "Companies routinely indicate that it's VirtualScopics' advanced technology coupled with our highly experienced and responsive project team that leads them to select us for their studies."

About VirtualScopics, I
'/>"/>

SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit
2. VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement
3. Nasdaq Grants VirtualScopics Request for Continued Listing
4. Shires Project Playground Gives Boost to Philadelphia
5. Enerkem announces plans to enter the United States with next-generation biofuels project in Mississippi
6. Canadian Government Announces Funding for Leading Biotechnology Firms Project
7. Photos: Project Runways Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldnt Let Psoriasis Impact Personal Style
8. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
9. Cord Blood America Restructures Debt; Projects to be Cash Flow Positive
10. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
11. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... New York, NY (PRWEB) June 17, 2013 ... to announce the launch of the Chief Medical Officer Summit ... CMO West will take place in San Francisco on ... , For the first time, West Coast Chief Medical ... idea from Dr. Elizabeth Stoner, Managing Director of MPM Capital. ...
(Date:6/17/2013)... 17, 2013 Z Trim Holdings, Inc. ... providing value-added ingredients to a variety of industries, ... new meat application at this year,s annual Institute ... Chicago , July 13-16. The Company will ... expensive/chemically-modified ingredients in meat products thereby helping manufacturers ...
(Date:6/17/2013)... June 17, 2013 ... announced the addition of the "North ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics- Forecasts ... ,      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/17/2013)... As interest increases in developing novel biomarker and ... need to keep up with the pace of new ... first in a series titled “Better Methods for Novel ... range of technologies, introduces a novel method for more ... than either ELISA or traditional LCMS can achieve. , ...
Breaking Biology Technology:Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3Quantitative Analysis of Biomarkers, New Life Science Webinar Hosted by Xtalks 2
... SANTA BARBARA, Calif., Nov. 15, 2011 FindTheBest,s Private ... parents seeking an accredited storage facility for their newborn,s cord ... and highly sensitive decision to make, particularly for families with ... parents a way to make the most informed decision when ...
... N.J., Nov. 15, 2011 Palatin Technologies, Inc. (NYSE ... targeted, receptor-specific peptide therapeutics for the treatment of diseases ... announced results for its first quarter ended September 30, ... or $(0.10) per basic and diluted share, for the ...
... 2011 A new retrospective subanalysis ... mesylate) capsules 150mg twice daily reduced the risk ... in patients with non-valvular atrial fibrillation (NVAF) irrespective ... with no significant interaction for major bleeding events.(1) ...
Cached Biology Technology:Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 2Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 3Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 4Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 2New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 4New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 6New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 7New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 8
(Date:6/17/2013)... 2013 An international team led by scientists at ... Institute and Albert Einstein College of Medicine of Yeshiva ... that attacks the tuberculosis (TB) bacterium in two different ... solve one of the major global health crises of ... strains," said Peter G. Schultz, the Scripps Family Chair ...
(Date:6/17/2013)... professors in Wayne State University,s Department of Physics ... Research Experience for Undergraduates (REU) program. This program ... cutting-edge research in astrophysics, and in particle and ... Ph.D., professor of physics in Wayne State,s College ... director of the grant, the student participants will ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4Wayne State welcomes undergraduates from around the US for physics research experience 2'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... DNA mutations may shepherd in an era of small, ... of genes that harbor disease. , Joseph Wang, director ... Biodesign Institute at ASU, led a team effort that ... and nanotechnology to fashion nanocrystals that can act as ...
... the plagues of the Middle Ages have made around 10% ... time that these individuals carry a genetic mutation (known as ... the immune system but have been unable to account for ... low levels in areas bordering the Mediterranean. , They have ...
... team of researchers at Johns Hopkins Medical Institutions in ... (PET/CT) scans may help physicians identify new, unexpected malignant ... the May issue of the Society of Nuclear Medicine's ... additional lesions in patients known to have cancer," said ...
Cached Biology News:Bioelectronic ‘signatures?hold key to DNA mutations 2First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2
...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: